An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice

Mohammed Saji Salahudeen, Prasad S. Nishtala

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.

Original languageEnglish
Pages (from-to)165-175
Number of pages11
JournalSaudi Pharmaceutical Journal
Volume25
Issue number2
Early online date9 Jul 2016
DOIs
Publication statusPublished - 1 Feb 2017

Fingerprint

Ligands
Pharmaceutical Preparations
Pharmacology
Sigmoid Colon
Binding Sites
Drug Therapy

Keywords

  • Competitive binding
  • E model
  • Fractional occupancy
  • Ligand binding
  • Pharmacodynamic model
  • Pharmacodynamics
  • Receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. / Salahudeen, Mohammed Saji; Nishtala, Prasad S.

In: Saudi Pharmaceutical Journal, Vol. 25, No. 2, 01.02.2017, p. 165-175.

Research output: Contribution to journalReview article

@article{30080db9a5814ad5a735fe1c87ba8c19,
title = "An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice",
abstract = "The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.",
keywords = "Competitive binding, E model, Fractional occupancy, Ligand binding, Pharmacodynamic model, Pharmacodynamics, Receptor",
author = "Salahudeen, {Mohammed Saji} and Nishtala, {Prasad S.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jsps.2016.07.002",
language = "English",
volume = "25",
pages = "165--175",
journal = "Saudi Pharmaceutical Journal",
issn = "1319-0164",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice

AU - Salahudeen, Mohammed Saji

AU - Nishtala, Prasad S.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.

AB - The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD models examine plasma concentration and effect relationship. It can predict the archetypal effect ([Formula: see text]) of a drug as a function of the drug concentration ([Formula: see text]) and estimate an unknown PD parameter ([Formula: see text]). The PD models have been described as fixed, linear, log-linear, [Formula: see text], sigmoid [Formula: see text], and indirect PD response. Ligand binding model is an example of a PD model that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the receptor site. The pharmacological effect is produced by the drug binding to the receptor to either activate or antagonise the receptor. Ligand binding models describe a system of interacting components, i.e. the interaction of one or more ligands with one or more binding sites. The [Formula: see text] model is the central method that provides an empirical justification for the concentration/dose-effect relationship. However, for ligand binding models justification is provided by theory of receptor occupancy. In essence, for ligand binding models, the term [Formula: see text] is best used to describe the fraction of receptors occupied at a particular ligand concentration. It is stated that the [Formula: see text], which means the effect of a drug should depend on the fraction of receptors that are occupied. In the future, network-based systems pharmacology models using ligand binding principles could be an effective way of understanding drug-related adverse effects. This will facilitate and strengthen the development of rational drug therapy in clinical practice.

KW - Competitive binding

KW - E model

KW - Fractional occupancy

KW - Ligand binding

KW - Pharmacodynamic model

KW - Pharmacodynamics

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=84997216970&partnerID=8YFLogxK

U2 - 10.1016/j.jsps.2016.07.002

DO - 10.1016/j.jsps.2016.07.002

M3 - Review article

VL - 25

SP - 165

EP - 175

JO - Saudi Pharmaceutical Journal

JF - Saudi Pharmaceutical Journal

SN - 1319-0164

IS - 2

ER -